CY1728A - Indole derivatives - Google Patents

Indole derivatives

Info

Publication number
CY1728A
CY1728A CY172894A CY172894A CY1728A CY 1728 A CY1728 A CY 1728A CY 172894 A CY172894 A CY 172894A CY 172894 A CY172894 A CY 172894A CY 1728 A CY1728 A CY 1728A
Authority
CY
Cyprus
Prior art keywords
alkyl
compounds
disclosed
indole derivatives
headache
Prior art date
Application number
CY172894A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878719167A external-priority patent/GB8719167D0/en
Priority claimed from GB888814002A external-priority patent/GB8814002D0/en
Priority claimed from GB888814481A external-priority patent/GB8814481D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1728A publication Critical patent/CY1728A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY172894A 1987-08-13 1994-05-06 Indole derivatives CY1728A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878719167A GB8719167D0 (en) 1987-08-13 1987-08-13 Chemical compounds
GB888814002A GB8814002D0 (en) 1988-06-14 1988-06-14 Chemical compounds
GB888814481A GB8814481D0 (en) 1988-06-17 1988-06-17 Chemical compounds
GB8819200A GB2208646B (en) 1987-08-13 1988-08-12 Indole derivatives

Publications (1)

Publication Number Publication Date
CY1728A true CY1728A (en) 1994-05-06

Family

ID=27263551

Family Applications (1)

Application Number Title Priority Date Filing Date
CY172894A CY1728A (en) 1987-08-13 1994-05-06 Indole derivatives

Country Status (28)

Country Link
US (1) US4997841A (lv)
EP (1) EP0303507B1 (lv)
JP (1) JPH0633252B2 (lv)
KR (1) KR0131327B1 (lv)
AT (1) ATE92057T1 (lv)
AU (1) AU611469B2 (lv)
CA (1) CA1310968C (lv)
CY (1) CY1728A (lv)
CZ (1) CZ404291A3 (lv)
DE (2) DE3882614T2 (lv)
DK (1) DK172696B1 (lv)
ES (1) ES2058292T3 (lv)
FI (1) FI92397C (lv)
GB (1) GB2208646B (lv)
HK (1) HK86793A (lv)
HU (1) HU211576A9 (lv)
IE (1) IE61488B1 (lv)
IL (1) IL87437A0 (lv)
LU (1) LU90160I2 (lv)
LV (1) LV5736B4 (lv)
NL (1) NL970035I2 (lv)
NO (2) NO174052C (lv)
NZ (1) NZ225820A (lv)
PH (1) PH24976A (lv)
PT (1) PT88255B (lv)
SG (1) SG65393G (lv)
SK (1) SK281495B6 (lv)
UY (1) UY23657A1 (lv)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
HU219974B (hu) * 1990-06-07 2001-10-28 Astrazeneca Ab, Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
TW222631B (lv) * 1991-07-15 1994-04-21 Duphar Int Res
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
KR950702978A (ko) * 1992-08-05 1995-08-23 폴 에이. 리처 아미드 유도체(Amide derivatives)
GB9320115D0 (en) * 1993-09-29 1993-11-17 Glaxo Group Ltd Process
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731224B1 (fr) * 1995-03-02 1997-05-30 Pf Medicament Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
WO1997033579A1 (en) * 1996-03-13 1997-09-18 Glaxo Group Limited Medicaments comprising 5ht1-like receptor agonists with an increased absorption
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
PT1305307E (pt) * 2000-07-21 2004-09-30 Lundbeck & Co As H Derivados de indole eficazes no tratamento de doencas do sistema nervoso central
JP2004517081A (ja) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
US20060110328A1 (en) * 2004-11-24 2006-05-25 Cagle Gerald D Method of delivering nasal spray
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
WO2008056378A2 (en) * 2006-11-09 2008-05-15 Natco Pharma Limited Novel process for the preparation of naratriptan hydrochloride
WO2008072257A2 (en) * 2006-12-12 2008-06-19 Ind-Swift Laboratories Limited Process for the preparation of indole derivatives
WO2009016466A2 (en) * 2007-07-30 2009-02-05 Orchid Chemicals & Pharmaceuticals Limited A process for the preparation of naratriptan hydrochloride
WO2009118753A2 (en) * 2008-03-07 2009-10-01 Usv Limited Process for preparation of naratriptan hydrochloride
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
WO2010004580A2 (en) * 2008-07-11 2010-01-14 Ind-Swift Laboratories Limited Process for preparing indole derivatives
WO2010084507A2 (en) * 2008-07-15 2010-07-29 Sun Pharmaceutical Industries Ltd. Process for the preparation of n-methyl-2-[3-(1-methyl-4-piperidyl)-1h-indol-5-yl]-ethanesulfonamide and its acid addition salts
AU2010284832A1 (en) * 2009-08-20 2012-02-09 Cipla Limited A process for the synthesis of naratriptan
CN102276581B (zh) * 2011-08-05 2013-06-12 上海师范大学 N-取代四氢吡啶连吲哚类化合物及其制备方法及应用
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
AU584142B2 (en) * 1984-12-04 1989-05-18 Glaxo Group Limited Indole derivatives
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NO174052B (no) 1993-11-29
NO1998008I1 (no) 1998-02-05
KR0131327B1 (en) 1998-04-17
GB8819200D0 (en) 1988-09-14
DE3882614D1 (de) 1993-09-02
DE3882614T2 (de) 1993-11-18
NO174052C (no) 1994-03-09
AU2069288A (en) 1989-02-16
EP0303507A2 (en) 1989-02-15
KR890003731A (ko) 1989-04-17
EP0303507A3 (en) 1990-09-19
DK455488D0 (da) 1988-08-12
LV5736A4 (lv) 1996-06-20
NO883587L (no) 1989-02-14
FI92397C (fi) 1994-11-10
DE19775082I2 (de) 2006-04-27
AU611469B2 (en) 1991-06-13
NL970035I1 (nl) 1997-11-03
HK86793A (en) 1993-08-27
SG65393G (en) 1993-08-06
JPH01207288A (ja) 1989-08-21
IE61488B1 (en) 1994-11-02
ES2058292T3 (es) 1994-11-01
LV5736B4 (lv) 1997-06-20
PH24976A (en) 1990-12-26
CA1310968C (en) 1992-12-01
DK455488A (da) 1989-02-14
US4997841A (en) 1991-03-05
IL87437A0 (en) 1989-01-31
PT88255A (pt) 1989-06-30
SK281495B6 (sk) 2001-04-09
LU90160I2 (fr) 1998-01-14
CZ404291A3 (en) 1993-04-14
HU211576A9 (en) 1995-12-28
GB2208646A (en) 1989-04-12
NL970035I2 (nl) 1998-01-05
GB2208646B (en) 1991-06-26
IE882477L (en) 1989-02-13
JPH0633252B2 (ja) 1994-05-02
UY23657A1 (es) 1994-02-25
FI883744A0 (fi) 1988-08-12
SK404291A3 (en) 2000-09-12
DK172696B1 (da) 1999-05-31
ATE92057T1 (de) 1993-08-15
FI92397B (fi) 1994-07-29
EP0303507B1 (en) 1993-07-28
PT88255B (pt) 1995-03-01
NO883587D0 (no) 1988-08-12
NZ225820A (en) 1990-09-26
FI883744A (fi) 1989-02-14

Similar Documents

Publication Publication Date Title
KR0131327B1 (en) Indole derivatives
DK391289D0 (da) Indolderivater
IL93337A0 (en) Indole derivatives and pharmaceutical compositions containing them
MY103509A (en) Indole derivatives.